WILLIAM R RINGO
CIK 1238325 · Chief Executive Officer · last filed 2025-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.79M
Companies
12
Total Filings
153
Lifetime Open-Market Net
-$4.32M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ASMB | Director | 1,455 | $26.97 | $39.2K | -$510.4K | 23 | 2025-06-09 |
| Sensei Biotherapeutics, Inc. (SNSE) Delisted | Director | 1,170 | $13.85 | $16.2K | $0 | 4 | 2025-05-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Chief Executive Officer | 0 | $38.00 | $0 | -$1.78M | 14 | 2021-04-19 |
| DERM | Director | 6,000 | $6.43 | $38.6K | -$165.7K | 17 | 2019-06-14 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | 10,000 | $178.75 | $1.79M | -$374.3K | 16 | 2019-06-12 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 31,800 | $0.18 | $5.6K | -$1.10M | 15 | 2017-09-22 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | — | $58.70 | — | $0 | 4 | 2016-05-19 |
| ASSEMBLY BIOSCIENCES, INC. (VTUS) Delisted | Director | 20,465 | — | — | $0 | 1 | 2014-07-14 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Director | 9,837 | — | — | -$400.3K | 7 | 2013-04-01 |
| PFE | Senior Vice President | 255,139 | $26.31 | $6.71M | $0 | 37 | 2010-04-01 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Director | 3,000 | — | — | $0 | 2 | 2007-06-21 |
| INSPIRE PHARMACEUTICALS INC (ISPH) Delisted | Director | — | — | — | $0 | 1 | 2007-06-12 |
Recent Filings · Page 9 of 16
153 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-24 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Exer (M) | — | $0 | EDGAR |
| 2015-06-16 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-15 | DERM | Grant (A) | — | $0 | EDGAR |
| 2015-06-03 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$14.1K | EDGAR |
| 2015-06-01 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2015-05-22 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$20.3K | EDGAR |
| 2015-04-08 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$18.8K | EDGAR |
| 2015-03-04 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$23.8K | EDGAR |
| 2015-02-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$13.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.